NBIO 0.04 Nascent Biotech, Inc.
| Range: | 0.0303-0.28 | Vol Avg: | 142282 | Last Div: | 0 | Changes: | 0.02 |
| Beta: | -3.27 | Cap: | 0.01B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Thu Dec 03 2009 | Empoloyees: | |||
| CUSIP: | 63108Q101 | CIK: | 0001622057 | ISIN: | US63108Q1013 | Country: | US |
| CEO: | Mr. Sean Carrick | Website: | https://www.nascentbiotech.com | ||||
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow